Evidence map›Paper›PMID 31667665›Full record

ArticleMedical oncology (Northwood, London, England)2019

Can synthetic lethality approach be used with DNA repair genes for primary and secondary MDS?

Howard Lopes Ribeiro Junior, Roberta Taiane Germano de Oliveira, Daniela de Paula Borges, Marília Braga Costa, Izabelle Rocha Farias, Antônio Wesley Araújo Dos Santos, Silvia Maria Meira Magalhães, Ronald Feitosa Pinheiro

Abstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Howard Lopes Ribeiro JuniorCancer Cytogenomic Laboratory, Center for Research and Drug Development (NPDM), Federal University of Ceara, 1000 Coronel, Nunes de Melo St. Rodolfo Teófilo, Fortaleza, Ceara, 60430-275, Brazil.
Roberta Taiane Germano de OliveiraCancer Cytogenomic Laboratory, Center for Research and Drug Development (NPDM), Federal University of Ceara, 1000 Coronel, Nunes de Melo St. Rodolfo Teófilo, Fortaleza, Ceara, 60430-275, Brazil.
Daniela de Paula BorgesCancer Cytogenomic Laboratory, Center for Research and Drug Development (NPDM), Federal University of Ceara, 1000 Coronel, Nunes de Melo St. Rodolfo Teófilo, Fortaleza, Ceara, 60430-275, Brazil.
Marília Braga CostaCancer Cytogenomic Laboratory, Center for Research and Drug Development (NPDM), Federal University of Ceara, 1000 Coronel, Nunes de Melo St. Rodolfo Teófilo, Fortaleza, Ceara, 60430-275, Brazil.
Izabelle Rocha FariasCancer Cytogenomic Laboratory, Center for Research and Drug Development (NPDM), Federal University of Ceara, 1000 Coronel, Nunes de Melo St. Rodolfo Teófilo, Fortaleza, Ceara, 60430-275, Brazil.
Antônio Wesley Araújo Dos SantosCancer Cytogenomic Laboratory, Center for Research and Drug Development (NPDM), Federal University of Ceara, 1000 Coronel, Nunes de Melo St. Rodolfo Teófilo, Fortaleza, Ceara, 60430-275, Brazil.
Silvia Maria Meira MagalhãesCancer Cytogenomic Laboratory, Center for Research and Drug Development (NPDM), Federal University of Ceara, 1000 Coronel, Nunes de Melo St. Rodolfo Teófilo, Fortaleza, Ceara, 60430-275, Brazil.
Ronald Feitosa PinheiroCancer Cytogenomic Laboratory, Center for Research and Drug Development (NPDM), Federal University of Ceara, 1000 Coronel, Nunes de Melo St. Rodolfo Teófilo, Fortaleza, Ceara, 60430-275, Brazil. pinheirorfeitosa@gmail.com.ORCID http://orcid.org/0000-0003-3546-0974
Universidade Federal do Ceará · BR

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 420501/2018-5Conselho Nacional de Desenvolvimento Científico e Tecnológico 424542/2016-1
6 · The paper itself

Abstract

Cancer-specific defects in DNA repair pathways create the opportunity to employ synthetic lethality approach. Recently, GEMA (gene expression and mutation analysis) approach detected insufficient expression of BRCA or NHEJ (non-homologous end joining) to predict PARP inhibitors response. We evaluated a possible role of DNA repair pathways using gene expression of single-strand break (XPA, XPC, XPG/ERCC5, CSA/ERCC8, and CSB/ERCC6) and double-strand break (ATM, BRCA1, BRCA2, RAD51, XRCC5, XRCC6, LIG4) in 92 patients with myelodysplastic syndrome (73 de novo, 9 therapy-related (t-MDS). Therapy-related MDS (t-MDS) demonstrated a significant downregulation of axis BRCA1-BRCA2-RAD51 comparing to normal controls (p = 0.048, p = 0.001, p = 0.001). XRCC6 showed significantly low expression in de novo MDS comparing to controls (p = 0.039) and for patients who presented chromosomal abnormalities (p = 0.047). Downregulation of LIG4 was consistently associated with poor prognostic markers in de novo MDS (hemoglobin < 8 g/dL (p = 0.040), neutrophils < 800/mm

Indexed as

Synthetic Lethal MutationsAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsDNA Ligase ATPDNA Repair EnzymesDown-RegulationFemaleHumansKu AutoantigenMaleMiddle AgedMyelodysplastic SyndromesPoly(ADP-ribose) Polymerase InhibitorsDNA Ligase ATPDNA Repair EnzymesKu AutoantigenLIG4 protein, humanPoly(ADP-ribose) Polymerase InhibitorsXrcc6 protein, humanDNA repairGene expressionMyelodysplastic syndromeSynthetic lethality

Identifiers

PMID31667665
OpenAlexW2982657615

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.